ProCE Banner Activity


Weighing in on Optimal Management of VTE in Patients With Obesity


A variety of direct oral anticoagulants (DOACs) are approved for the treatment of venous thromboembolism (VTE), with different indications that require clinicians to understand how to use them in appropriate patients. In this 1-hour interactive multimedia activity, expert faculty discuss the latest guidance and clinical evidence on the safety and efficacy of DOACs in patients with obesity. The program includes an interactive case study, patient-clinician video, and downloadable slides.

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: April 15, 2022

Expiration: April 14, 2023

No longer available for credit.



Christian T. Ruff

Christian T. Ruff, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Director of General Cardiology
Brigham and Women's Hospital
Boston, Massachusetts

Daniel Thibodeau

Daniel Thibodeau, DHSc, MHP, PA-C

Physician Assistant Program
Doctor of Medical Science Program
Eastern Virginia Medical School
Physician Assistant
Division of Cardiology
Sentara Medical Group
Sentara Health Systems
Norfolk, Virginia


This activity is supported by educational grants from the Bristol-Myers Squibb and Pfizer Alliance; and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Provided by

ProCE Banner


Bristol Myers Squibb

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Pfizer Alliance

Target Audience

NPs and PAs in primary care

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the safety and efficacy profiles for DOACs vs warfarin in patients with obesity

  • Develop a treatment plan for a patient with VTE and obesity utilizing the most recent clinical evidence, expert consensus recommendations, and patient specific factors

  • Assess risk factors for VTE recurrence and bleeding to determine the appropriate length of therapy for VTE treatment in a patient with obesity


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Ruff: consultant/advisor/speaker: Anthos, Bayer, Bristol-Myers Squibb, Janssen, Pfizer; researcher: Anthos, AstraZeneca, National Institutes of Health; researcher/consultant/advisor/speaker: Boehringer Ingelheim, Daiichi Sankyo.

Mr Thibodeau: has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

The estimated time to complete this activity is 1.00 hour.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.

Release date: April 15, 2022
Expiration date: April 14, 2023


Interactive, audio-enhanced slide lecture


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Mary Knudtson, DNSc, NP, FAAN, University of California, Irvine, Irvine, California

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until April 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.